Tag: Silo Pharma - Psilocybin Alpha

New: Psychedelics 2021: A Year in Review

Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange

Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange

Post published:December 14, 2021
Post category:Press Release

Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

Post published:December 2, 2021
Post category:Press Release

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

Post published:November 18, 2021
Post category:Press Release

Silo Pharma Reports Third Quarter Results and Operating Highlights

Silo Pharma Reports Third Quarter Results and Operating Highlights

Post published:November 11, 2021
Post category:Press Release

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease

Post published:October 27, 2021
Post category:Press Release

Silo Pharma Advances Psychedelic Patent Portfolio

Silo Pharma Advances Psychedelic Patent Portfolio

Post published:August 25, 2021
Post category:Press Release

Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

Post published:July 27, 2021
Post category:Press Release

Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

Post published:July 12, 2021
Post category:Press Release

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

Post published:June 8, 2021
Post category:Press Release

Silo Pharma Submits Application for NASDAQ up-listing

Silo Pharma Submits Application for NASDAQ up-listing

Post published:May 25, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.